.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

Spotlight

In-person and virtual events just for HCPs

SpecialtySee All >

Breast Cancer
Lung Cancer
Gastrointestinal Cancer
Genitourinary Cancers
Ovarian Cancer
Prostate Cancer
Melanoma & Skin Cancer
MCL
MPN
CAR T-cell Therapy
Chronic Lymphocytic Leukemia
Gynecologic Oncology
Hematologic Oncology
Immuno-Oncology
Multiple Myeloma
Urothelial Cancer

Advertise
About OncLive
Editorial Board
MJH Life Sciences brands
Contact Us
Privacy
Terms & Conditions
Do Not Sell My Information

2 Clarke Drive
Suite 100
Cranbury, NJ 08512

Emerging Strategies for Renal Cell Carcinoma

EP. 1: The Biology of RCC and Improved Treatment Outcomes

December 14th 2020

EP. 2: Tumor Biology in Favorable to Poor-Risk RCC

December 14th 2020

EP. 3: Improved Outcomes With Novel and Combination Therapies

December 14th 2020

EP. 4: Risk Assessment and Diagnostic Work-up

December 14th 2020

EP. 5: Newly Diagnosed RCC: KEYNOTE-426 and CheckMate-214

December 14th 2020

EP. 6: The Role of VEGF TKI Monotherapy

December 14th 2020

EP. 7: Impact of the Phase 3 CheckMate 9ER Trial on Practice

December 14th 2020

EP. 8: The Role of Combination Treatment in RCC

December 14th 2020

EP. 9: The Future Treatment Landscape of RCC

December 14th 2020

EP. 10: Emerging Therapies for Relapsed/Refractory MRCC

December 14th 2020